查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1576568

贝特类药物市场：按药物类型、应用、患者属性、分销管道、剂型、最终用户、给药途径和购买模式分類的全球预测 - 2025-2030

Fibrate Drugs Market by Drug Type, Application, Patient Demographics, Distribution Channel, Formulation, End User, Route Of Administration, Mode Of Purchase - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，贝特类药物市值为34.5亿美元，预计到2024年将达到37.2亿美元，复合年增长率为7.05%，到2030年将达到55.6亿美元。

贝特类药物市场主要集中在透过降低三酸甘油酯水平和增加高密度脂蛋白（HDL）胆固醇来治疗血脂血脂异常症的调脂药物。贝特类药物的需求在于其在管理与高血脂症相关的心血管危险因子方面的有效性，特别是对于无法使用他汀类药物或他汀类药物疗效不足的患者。贝特类药物的主要用途包括单一疗法或与其他降脂疗法合併治疗高三酸甘油脂血症和混合型血脂异常等病症。主要使用范围为医院、诊所等医疗机构，以及仅靠生活方式介入无法满足治疗要求时的私人处方。

主要市场统计
基准年[2023] 34.5亿美元
预测年份 [2024] 37.2亿美元
预测年份 [2030] 55.6亿美元
复合年增长率（%） 7.05%

市场成长受到全球心血管疾病和肥胖症发病率上升、老年人口数量增加以及人们对预防性医疗保健措施意识不断增强的影响。不断增加的市场开拓和新药核准也为该市场提供了利润丰厚的机会。然而，潜在的增长受到胃肠道不适和肝毒性等副作用以及来自他汀类药物等更成熟的降胆固醇药物的竞争的限制，后者通常具有更有利的副作用。

为了利用成长机会，公司应专注于严格的研究和开发，旨在提高贝特类药物的安全性和有效性。开发可最大限度减少副作用的联合治疗和探索个人化医疗方法等创新可以提供竞争优势。此外，透过策略伙伴关係和对新兴市场的投资扩大市场进入可以扩大我们的消费者基础。也必须谨慎应对严格的监管要求和专利到期等挑战。公司应透过确保合规性来确保贝特类市场空间的持续成长和发展，同时继续将製药进步与未满足的临床需求结合。

市场动态：快速发展的贝特类市场的关键市场洞察

供需的动态交互作用正在改变贝特类市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 成人和老年人群中高血脂症患者迅速增加
    • 製药公司进军潜力开拓的新兴市场
    • 增强贝特类药物疗效的药物传递系统的进展
    • 增加医疗保健支出和使用现代化医疗设施的机会
  • 市场限制因素
    • 新贝特製剂和变体的研发高成本
  • 市场机会
    • 针对脂质代谢相关遗传疾病的贝特类药物的利基市场
    • 有机会透过贝特类药物个人化客製化患者治疗计划
    • 兽医高血脂症治疗对贝特类药物的需求
  • 市场挑战
    • 影响各地区贝特类核准流程的严格监管指南

波特五力：驾驭贝特类市场的策略工具

波特的五力架构是了解贝特类药物市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解贝特类药物市场的外部影响

外部宏观环境因素对贝特类药物市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解贝特类药物市场竞争状况

对贝特类药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV定位矩阵贝特类市场供应商绩效评估

FPNV定位矩阵是评估fibrate市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划贝特类药物市场的成功之路

对于希望加强在全球市场的影响力的公司来说，对贝特类药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 成人和老年人高血脂症病例迅速增加
      • 製药公司在有潜力的新兴市场扩张
      • 药物输送系统的进步提高了贝特类药物的疗效
      • 医疗保健成本上升和现代医疗设施的普及
    • 抑制因素
      • 新贝特製剂和变体的研发高成本
    • 机会
      • 针对脂质代谢相关遗传疾病的贝特类药物的利基市场
      • 使用贝特类药物进行个人化医疗为患者量身定制治疗计划的机会
      • 治疗动物高血脂症的兽药对贝特类药物的需求
    • 任务
      • 严格的监管指引影响了各地区贝特类药物的核准流程
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 贝特类药物市场（依类型）

  • 苯札贝特
  • 安妥贝特
  • 非诺贝特
    • 非专利仿製药
  • 吉非贝齐

第七章贝特类药物市场：依应用分类

  • 心血管疾病
  • 血脂异常症
  • 高血脂症
  • 高三酸甘油脂血症

第 8 章依病患分层分類的贝特类药物市场

  • 成人
  • 老年人
  • 小儿科

第九章贝特类药物市场：依通路分类

  • 药局
  • 医院药房
  • 网路药房
  • 零售药房

第10章 贝特类处方药市场

  • 胶囊
  • 暂停
  • 药片

第十一章贝特药物市场：依最终使用者分类

  • 诊所
  • 居家护理
  • 医院

第十二章贝特类药物市场：依给药途径

  • 可注射的
  • 口服

第十三章 贝特类药物市场（依采购方式）

  • 在商店
  • 根据处方笺

第十四章 北美及南美贝特类药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十五章亚太地区贝特类药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十六章 欧洲、中东和非洲贝特类药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十七章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C0478

The Fibrate Drugs Market was valued at USD 3.45 billion in 2023, expected to reach USD 3.72 billion in 2024, and is projected to grow at a CAGR of 7.05%, to USD 5.56 billion by 2030.

The fibrate drugs market is defined by its focus on lipid-modifying agents primarily used to treat dyslipidemia by lowering triglyceride levels and increasing high-density lipoprotein (HDL) cholesterol. The necessity for fibrate drugs lies in their effectiveness in managing cardiovascular risk factors associated with hyperlipidemia, especially for patients who cannot use or do not respond sufficiently to statins. Key applications of fibrate drugs include their use as standalone treatments or in combination with other lipid-lowering therapies in the management of conditions like hypertriglyceridemia and mixed dyslipidemia. End-use scope predominantly involves medical institutions, including hospitals and clinics, along with individual prescriptions where lifestyle interventions alone do not meet therapeutic requirements.

KEY MARKET STATISTICS
Base Year [2023] USD 3.45 billion
Estimated Year [2024] USD 3.72 billion
Forecast Year [2030] USD 5.56 billion
CAGR (%) 7.05%

Market growth is influenced by the rise in global cases of cardiovascular diseases and obesity, a growing geriatric population, and increased awareness about preventative healthcare measures. The rise in drug development and approval of novel therapies also presents lucrative opportunities in this market. However, potential growth is limited by side effects such as gastrointestinal discomfort or liver toxicity and the competition from more established cholesterol-lowering agents like statins, which often have a more favorable side effect profile.

To exploit growth opportunities, companies should focus on rigorous research and development aimed at enhancing the safety and efficacy profile of fibrate drugs. Innovations like developing combination therapies that minimize side effects or exploring personalized medicine approaches could provide competitive advantages. Furthermore, expanding market access through strategic partnerships and investments in emerging markets can broaden the consumer base. Challenges such as stringent regulatory requirements and patent expirations also need to be navigated carefully. Businesses should ensure compliance while continuously seeking to align pharmaceutical advancements with unmet clinical needs, thereby ensuring sustainable growth and development in the fibrate drugs market domain.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Fibrate Drugs Market

The Fibrate Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Surging cases of hyperlipidemia among adult and geriatric population
    • Expansion of pharmaceutical companies in emerging markets with untapped potential
    • Advancements in drug delivery systems enhancing the efficacy of fibrate drugs
    • Rise in healthcare expenditure and access to modern medical facilities
  • Market Restraints
    • High costs associated with research and development of new fibrate formulations and variants
  • Market Opportunities
    • Niche market for fibrate drugs targeting genetic disorders involving lipid metabolism
    • Opportunities in personalized medicine through fibrate drugs for customized patient treatment plans
    • Demand for fibrate drugs in veterinary medicine for treating hyperlipidemia in animals
  • Market Challenges
    • Strict regulatory guidelines impacting the approval process of fibrate drugs in different regions

Porter's Five Forces: A Strategic Tool for Navigating the Fibrate Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Fibrate Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Fibrate Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Fibrate Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Fibrate Drugs Market

A detailed market share analysis in the Fibrate Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Fibrate Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Fibrate Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Fibrate Drugs Market

A strategic analysis of the Fibrate Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Fibrate Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Allergan plc, Amgen Inc., AstraZeneca plc, Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Cipla Limited, Daiichi Sankyo Company, Limited, GlaxoSmithKline plc, Lupin Limited, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Limited, and Zydus Cadila.

Market Segmentation & Coverage

This research report categorizes the Fibrate Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Bezafibrate, Clofibrate, Fenofibrate, and Gemfibrozil. The Fenofibrate is further studied across Generic Fenofibrate.
  • Based on Application, market is studied across Cardiovascular Diseases, Dyslipidemia, Hyperlipidemia, and Hypertriglyceridemia.
  • Based on Patient Demographics, market is studied across Adults, Elderly, and Pediatric.
  • Based on Distribution Channel, market is studied across Drug Stores, Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Formulation, market is studied across Capsules, Suspensions, and Tablets.
  • Based on End User, market is studied across Clinics, Homecare, and Hospitals.
  • Based on Route Of Administration, market is studied across Injectable and Oral.
  • Based on Mode Of Purchase, market is studied across Over The Counter and Prescription Based.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surging cases of hyperlipidemia among adult and geriatric population
      • 5.1.1.2. Expansion of pharmaceutical companies in emerging markets with untapped potential
      • 5.1.1.3. Advancements in drug delivery systems enhancing the efficacy of fibrate drugs
      • 5.1.1.4. Rise in healthcare expenditure and access to modern medical facilities
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with research and development of new fibrate formulations and variants
    • 5.1.3. Opportunities
      • 5.1.3.1. Niche market for fibrate drugs targeting genetic disorders involving lipid metabolism
      • 5.1.3.2. Opportunities in personalized medicine through fibrate drugs for customized patient treatment plans
      • 5.1.3.3. Demand for fibrate drugs in veterinary medicine for treating hyperlipidemia in animals
    • 5.1.4. Challenges
      • 5.1.4.1. Strict regulatory guidelines impacting the approval process of fibrate drugs in different regions
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Fibrate Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Bezafibrate
  • 6.3. Clofibrate
  • 6.4. Fenofibrate
    • 6.4.1. Generic Fenofibrate
  • 6.5. Gemfibrozil

7. Fibrate Drugs Market, by Application

  • 7.1. Introduction
  • 7.2. Cardiovascular Diseases
  • 7.3. Dyslipidemia
  • 7.4. Hyperlipidemia
  • 7.5. Hypertriglyceridemia

8. Fibrate Drugs Market, by Patient Demographics

  • 8.1. Introduction
  • 8.2. Adults
  • 8.3. Elderly
  • 8.4. Pediatric

9. Fibrate Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Drug Stores
  • 9.3. Hospital Pharmacies
  • 9.4. Online Pharmacies
  • 9.5. Retail Pharmacies

10. Fibrate Drugs Market, by Formulation

  • 10.1. Introduction
  • 10.2. Capsules
  • 10.3. Suspensions
  • 10.4. Tablets

11. Fibrate Drugs Market, by End User

  • 11.1. Introduction
  • 11.2. Clinics
  • 11.3. Homecare
  • 11.4. Hospitals

12. Fibrate Drugs Market, by Route Of Administration

  • 12.1. Introduction
  • 12.2. Injectable
  • 12.3. Oral

13. Fibrate Drugs Market, by Mode Of Purchase

  • 13.1. Introduction
  • 13.2. Over The Counter
  • 13.3. Prescription Based

14. Americas Fibrate Drugs Market

  • 14.1. Introduction
  • 14.2. Argentina
  • 14.3. Brazil
  • 14.4. Canada
  • 14.5. Mexico
  • 14.6. United States

15. Asia-Pacific Fibrate Drugs Market

  • 15.1. Introduction
  • 15.2. Australia
  • 15.3. China
  • 15.4. India
  • 15.5. Indonesia
  • 15.6. Japan
  • 15.7. Malaysia
  • 15.8. Philippines
  • 15.9. Singapore
  • 15.10. South Korea
  • 15.11. Taiwan
  • 15.12. Thailand
  • 15.13. Vietnam

16. Europe, Middle East & Africa Fibrate Drugs Market

  • 16.1. Introduction
  • 16.2. Denmark
  • 16.3. Egypt
  • 16.4. Finland
  • 16.5. France
  • 16.6. Germany
  • 16.7. Israel
  • 16.8. Italy
  • 16.9. Netherlands
  • 16.10. Nigeria
  • 16.11. Norway
  • 16.12. Poland
  • 16.13. Qatar
  • 16.14. Russia
  • 16.15. Saudi Arabia
  • 16.16. South Africa
  • 16.17. Spain
  • 16.18. Sweden
  • 16.19. Switzerland
  • 16.20. Turkey
  • 16.21. United Arab Emirates
  • 16.22. United Kingdom

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2023
  • 17.2. FPNV Positioning Matrix, 2023
  • 17.3. Competitive Scenario Analysis
  • 17.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Allergan plc
  • 3. Amgen Inc.
  • 4. AstraZeneca plc
  • 5. Aurobindo Pharma Limited
  • 6. Bristol-Myers Squibb Company
  • 7. Cipla Limited
  • 8. Daiichi Sankyo Company, Limited
  • 9. GlaxoSmithKline plc
  • 10. Lupin Limited
  • 11. Merck & Co., Inc.
  • 12. Mylan N.V.
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Sanofi S.A.
  • 16. Sun Pharmaceutical Industries Limited
  • 17. Takeda Pharmaceutical Company Limited
  • 18. Teva Pharmaceutical Industries Ltd.
  • 19. Torrent Pharmaceuticals Limited
  • 20. Zydus Cadila

LIST OF FIGURES

  • FIGURE 1. FIBRATE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. FIBRATE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL FIBRATE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL FIBRATE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL FIBRATE DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL FIBRATE DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2023 VS 2030 (%)
  • FIGURE 21. GLOBAL FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. AMERICAS FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 25. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 30. FIBRATE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 31. FIBRATE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. FIBRATE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL FIBRATE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL FIBRATE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. FIBRATE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL FIBRATE DRUGS MARKET SIZE, BY BEZAFIBRATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL FIBRATE DRUGS MARKET SIZE, BY CLOFIBRATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL FIBRATE DRUGS MARKET SIZE, BY GENERIC FENOFIBRATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL FIBRATE DRUGS MARKET SIZE, BY GEMFIBROZIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL FIBRATE DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DYSLIPIDEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HYPERLIPIDEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ELDERLY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL FIBRATE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL FIBRATE DRUGS MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL FIBRATE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL FIBRATE DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL FIBRATE DRUGS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL FIBRATE DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL FIBRATE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL FIBRATE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL FIBRATE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL FIBRATE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL FIBRATE DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL FIBRATE DRUGS MARKET SIZE, BY PRESCRIPTION BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES FIBRATE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. INDONESIA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. JAPAN FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. JAPAN FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 159. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. MALAYSIA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 168. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. PHILIPPINES FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 177. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. SINGAPORE FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 186. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. SOUTH KOREA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 195. TAIWAN FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. TAIWAN FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. TAIWAN FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 204. THAILAND FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 205. THAILAND FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. THAILAND FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 213. VIETNAM FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 214. VIETNAM FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. VIETNAM FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA FIBRATE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 232. DENMARK FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. DENMARK FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. DENMARK FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 241. EGYPT FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 242. EGYPT FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 243. EGYPT FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 250. FINLAND FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 251. FINLAND FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. FINLAND FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 259. FRANCE FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 260. FRANCE FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 261. FRANCE FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 268. GERMANY FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 269. GERMANY FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 270. GERMANY FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 277. ISRAEL FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 278. ISRAEL FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 279. ISRAEL FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 286. ITALY FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 287. ITALY FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 288. ITALY FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 291. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 295. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 296. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 297. NETHERLANDS FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 298. NIGERIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 299. NIGERIA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 300. NIGERIA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 304. NIGERIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 305. NIGERIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 306. NIGERIA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 307. NORWAY FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. NORWAY FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 309. NORWAY FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 310. NORWAY FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 311. NORWAY FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 313. NORWAY FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 314. NORWAY FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 315. NORWAY FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 316. POLAND FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. POLAND FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 318. POLAND FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 319. POLAND FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 320. POLAND FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 322. POLAND FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 323. POLAND FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 324. POLAND FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 325. QATAR FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. QATAR FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 327. QATAR FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 328. QATAR FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 329. QATAR FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 330. QATAR FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 331. QATAR FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 332. QATAR FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 333. QATAR FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 334. RUSSIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 335. RUSSIA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 336. RUSSIA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 337. RUSSIA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 338. RUSSIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 339. RUSSIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 340. RUSSIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 341. RUSSIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 342. RUSSIA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 343. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 344. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 345. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 346. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 347. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 348. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 349. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 350. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 351. SAUDI ARABIA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 352. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 353. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 354. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 355. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 356. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 357. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 358. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 359. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 360. SOUTH AFRICA FIBRATE DRUGS MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 361. SPAIN FIBRATE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 362. SPAIN FIBRATE DRUGS MARKET SIZE, BY FENOFIBRATE, 2018-2030 (USD MILLION)
  • TABLE 363. SPAIN FIBRATE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 364. SPAIN FIBRATE